Tamer Hellou, Clinical fellowship at Mayo Clinic Rochester, shared a post on LinkedIn:
“New publication in Blood Cancer Journal
Not all primary plasma cell leukemia is created equally.
We demonstrate that cumulative high-risk cytogenetic abnormalities confer stepwise inferior outcomes in primary plasma cell leukemia, while isolated t(11;14) defines a favorable biologic subset, emphasizing the need for risk-adapted, personalized treatment strategies.”
Title: Impact of t(11;14) primary cytogenetic abnormality and the cumulative effect of multiple high-risk cytogenetics at diagnosis on the outcomes of patients with primary plasma cell leukemia
Authors: Tamer Hellou, Shaji Kumar, Samhar Samer Alouch, Adrian Almodovar-Diaz, Angela Dispenzieri, Dragan Jevremovic, Francis Buadi, David Dingli, Saurabh Zanwar, Suzanne Hayman, Prashant Kapoor, Nelson Leung, Amie Fonder, Miriam Hobbs, Yi Lisa Hwa, Eli Muchtar, Rahma Warsame, Taxiarchis Kourelis, Joselle Cook, Moritz Binder, Nadine Abdallah, Yi Lin, Ronald Go, Mustaqeem Siddiqui, Robert Kyle, Morie Gertz, S Vincent Rajkumar, Wilson Gonsalves
Read the Full Article.
